# Kyntra Bio to Report Third Quarter 2026 Financial Results

- Published: 2026-11-13
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/kyntra-bio-to-report-third-quarter-2026-financial-results/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

SAN FRANCISCO, Nov. 13, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce third quarter 2026 financial results on Monday, November 16 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.

**Conference Call and Webcast Presentation**  
Kyntra Bio management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call <a href="https://www.globenewswire.com/Tracker?data=UiOT48ZpzvetgSAHPHQHqe1TTt8M3dsjzyxHJzMuW3isTp0lCX6OP136oMLDTTpuciAjEDMOQ3vKi2wnckhwuo746F-bLRWrbNH0Pz2HEfQ=" rel="nofollow">here</a>. To access the call by phone, please <a href="https://www.globenewswire.com/Tracker?data=aSXGV571NEkVhsLaDmQ7WYDOiz0QVb2r2Qw420z_lgiwQhAduhCAaDXS6H4NB6LY-iADK5hZ2-uEL7dDMx7PmcX9C8M-tf04EcaY27xs2wlQpuKNl9yG4z4EQCdZhGFlsz_1MfLMh-FjbE1E1aLEDJmZMF3hP_UYUG_c2U-I0XY=" rel="nofollow">register here,</a> and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the <a href="https://www.globenewswire.com/Tracker?data=dAO0wp16sj4HwcQ7dGu-0JCdBxOnVZUKZQeRwuCeRqyh-ELV2e9_ukUAAcMAp9xfYHvfZJZR-z_mVhBapS6SblBHMI1sQPXcSv0oZ84U6qk-7cZbgCYkztfrBh7aTmTQUKCrdi9RpwRUP3ASuIG8DUIEQ0hJcOjab3veaMzXxO0=" rel="nofollow">Events & Presentations</a> page on Kyntra Bio’s website.

**About Kyntra Bio**  
Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndromes (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=E0dnOijbbaHfDV4FgiQdbv95vQeqd3QCvp8hm6MjahcmvT8RQ1d0CLXAY87Y8YnMP7LKWXjf099Jex3t2IF5xNl8fFeTVKC7y65DiiMG7f9AHfjZaJtHeYEjkSaEhhOKIUwBJ76ICTtru79rzp7Pts4OxqlA4a7_Myo6i9AV_USV7FNRswE-ddqgWERORH3GAanYHVNWbKq6nmDW_r5vSGVhJdL3Biz6QandCeP2WzL42UxIIr_JZvSY8CCqvSXVp6O8PGZ__1_9tishwpYvFQ==" rel="nofollow">www.kyntrabio.com</a>.

**For Investor Inquiries:**  
David DeLucia, CFA  
Senior Vice President and Chief Financial Officer  
<a href="https://www.globenewswire.com/Tracker?data=1bKdb79XET66UbbZXnt0wXgXdyPrl46JEF5xp4NTlDqkYdfbxujvQ_eel9EkqF7FI7GsgVkqgrjyShcTlXF6VOGNF-CURoLTUR3Ppka7wqTIB1zx_l0Q9fwOz31B12xfsl2jQekOlx44SrS3qRZcYtPeKUNSm-Sop9DLCxCz4dLrea5BOerPStODw_aT3BLuo4u6hnzd7TEi04ptG6Z5dRf4a38b_vm3RfXqCfa-1GN1-2T8RQncBJFAmUlTTzXKGkYb26JiVdsYiFLNtTIvzg==" rel="nofollow">ir@kyntrabio.com</a> 

  
![](https://ml.globenewswire.com/media/ZDkxMjI0YTAtMzBkYy00MWU0LWE1MWQtYzM3ZDcxYTZhODY5LTEwMTk1MzYtMjAyNi0xMS0xMy1lbg==/tiny/Kyntra-Bio.png)

## Related

- [SS Innovations Strengthens Management Team in Preparation for Global Sales Expansion](https://healthcarenews.io/news/ss-innovations-strengthens-management-team-in-preparation-for-global-sales-expansion.md)
- [AIM ImmunoTech Approaches Major Clinical Inflection Point with Phase 2 Pancreatic Cancer Data Expected Q1 2027; Reports Third Quarter 2026 Financial Results](https://healthcarenews.io/news/aim-immunotech-approaches-major-clinical-inflection-point-with-phase-2-pancreatic-cancer-d.md)
- [PDS Biotech Reports Third Quarter 2026 Financial Results](https://healthcarenews.io/news/pds-biotech-reports-third-quarter-2026-financial-results.md)
- [Benitec Biopharma Releases First Quarter 2027 Fiscal-Year Financial Results and Provides Operational Update](https://healthcarenews.io/news/benitec-biopharma-releases-first-quarter-2027-fiscal-year-financial-results-and-provides-o.md)